By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sosei Group Corporation 

4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
Tokyo    102-0082  Japan
Phone: 81-0-3-5210-3290 Fax: 81-0-3-5210-3291


Company News
Sosei Group Corporation Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders 11/10/2016 2:41:08 PM
Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA) 9/28/2015 1:18:02 PM
Sosei Group Corporation Release: Planned Development Of Inhaled Triple Therapy QVM149 For Asthma 6/18/2015 1:11:55 PM
Sosei Group Corporation Acquires Jitsubo, A Leading Japanese Peptide Technology Company 12/12/2014 10:26:07 AM
Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. (PFE) In The UK 9/8/2014 11:21:19 AM
G2B Pharma Receives Project Financing From Sosei Group Corporation And Right To In-License Nasal Delivery Technologies From SNBL 8/13/2014 7:19:31 AM
Sosei Group Corporation Signs Distribution Agreement With FUJIFILM Pharma For Commercialization Of SO-1105 2/4/2014 9:15:33 AM
Sosei Group Corporation: Once-Daily Ultibro® Inhalation Capsules (QVA149) For COPD Launched In Japan 11/20/2013 9:36:38 AM
Sosei Group Corporation's First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Approved for the Treatment of COPD in Europe 9/23/2013 9:44:18 AM
Sosei Group Corporation: First in Class Once-Daily Dual Bronchodilator Ultibro Inhalation Capsules (QVA149) Approved for the Treatment of COPD in Japan 9/20/2013 10:14:33 AM